Literature DB >> 23146044

S100A12: a noninvasive marker of inflammation in inflammatory bowel disease.

Floor van de Logt1, Andrew S Day.   

Abstract

Inflammatory bowel diseases are incurable conditions that feature gut inflammation. Standard markers have inadequate sensitivity and specificity. S100A12 is a new fecal marker that has promise as a non-invasive indicator of gut inflammation. This article reviews recent studies focusing on S100A12 and highlights the current and potential roles of this biomarker.
© 2012 The Authors. Journal of Digestive Diseases © 2012 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23146044     DOI: 10.1111/1751-2980.12012

Source DB:  PubMed          Journal:  J Dig Dis        ISSN: 1751-2972            Impact factor:   2.325


  19 in total

Review 1.  Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease.

Authors:  Anet A Soubières; Andrew Poullis
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

Review 2.  Practical guidance on the use of faecal calprotectin.

Authors:  Matthew J Brookes; Simon Whitehead; Daniel R Gaya; Antony Barney Hawthorne
Journal:  Frontline Gastroenterol       Date:  2017-02-22

3.  The Human Antimicrobial Protein Calgranulin C Participates in Control of Helicobacter pylori Growth and Regulation of Virulence.

Authors:  Kathryn P Haley; Alberto G Delgado; M Blanca Piazuelo; Brittany L Mortensen; Pelayo Correa; Steven M Damo; Walter J Chazin; Eric P Skaar; Jennifer A Gaddy
Journal:  Infect Immun       Date:  2015-05-11       Impact factor: 3.441

4.  Noninvasive Markers of Disease Activity in Inflammatory Bowel Disease.

Authors:  Raluca Vrabie; Sunanda Kane
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-09

Review 5.  Biomarkers of Inflammatory Bowel Disease: From Classical Laboratory Tools to Personalized Medicine.

Authors:  Emilie Viennois; Yuan Zhao; Didier Merlin
Journal:  Inflamm Bowel Dis       Date:  2015-10       Impact factor: 5.325

Review 6.  Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives.

Authors:  Gian Eugenio Tontini; Maurizio Vecchi; Luca Pastorelli; Markus F Neurath; Helmut Neumann
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

Review 7.  Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease.

Authors:  Cristina-Sorina Cătană; Ioana Berindan Neagoe; Vasile Cozma; Cristian Magdaş; Flaviu Tăbăran; Dan Lucian Dumitraşcu
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

8.  S100A12 as a marker of worse cardiac output and mortality in pulmonary hypertension.

Authors:  Argyrios Tzouvelekis; Jose D Herazo-Maya; Changwan Ryu; Jen-Hwa Chu; Yingze Zhang; Kevin F Gibson; Percy K Adonteng-Boateng; Qin Li; Hongyi Pan; Benjamin Cherry; Ferhaan Ahmad; Hubert J Ford; Erica L Herzog; Naftali Kaminski; Wassim H Fares
Journal:  Respirology       Date:  2018-04-02       Impact factor: 6.424

9.  Serum omentin-1 as a disease activity marker for Crohn's disease.

Authors:  Yan Lu; Li Zhou; Lifeng Liu; Yan Feng; Li Lu; Xiaoyan Ren; Xinqian Dong; Weiwei Sang
Journal:  Dis Markers       Date:  2014-02-11       Impact factor: 3.434

10.  Extracellular vesicle-mediated endothelial apoptosis and EV-associated proteins correlate with COVID-19 disease severity.

Authors:  Balaji Krishnamachary; Christine Cook; Ashok Kumar; Leslie Spikes; Prabhakar Chalise; Navneet K Dhillon
Journal:  J Extracell Vesicles       Date:  2021-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.